Mirum Pharmaceuticals (NASDAQ:MIRM) Now Covered by Analysts at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research report report published on Wednesday, Marketbeat Ratings reports. The firm issued a buy rating and a $48.00 price target on the stock.

A number of other equities research analysts have also weighed in on MIRM. SVB Leerink dropped their price target on Mirum Pharmaceuticals from $44.00 to $43.00 and set an outperform rating on the stock in a research note on Monday, March 18th. JMP Securities boosted their price target on Mirum Pharmaceuticals from $69.00 to $72.00 and gave the stock an outperform rating in a research note on Thursday, March 14th. HC Wainwright restated a buy rating and set a $58.00 price target on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 2nd. Raymond James dropped their target price on Mirum Pharmaceuticals from $78.00 to $64.00 and set a strong-buy rating on the stock in a research report on Tuesday, December 19th. Finally, Cantor Fitzgerald reiterated an overweight rating and issued a $35.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, February 29th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of Buy and a consensus target price of $51.70.

Mirum Pharmaceuticals Trading Up 1.0 %

MIRM opened at $23.81 on Wednesday. Mirum Pharmaceuticals has a 1 year low of $23.29 and a 1 year high of $35.56. The company has a current ratio of 4.45, a quick ratio of 4.19 and a debt-to-equity ratio of 1.23. The business’s 50-day moving average is $26.89 and its two-hundred day moving average is $28.49.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 66.24% and a negative net margin of 86.33%. The business had revenue of $69.55 million for the quarter, compared to analysts’ expectations of $66.73 million. Sell-side analysts anticipate that Mirum Pharmaceuticals will post -1.29 EPS for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, CFO Eric Bjerkholt purchased 2,000 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was bought at an average cost of $25.80 per share, with a total value of $51,600.00. Following the completion of the acquisition, the chief financial officer now owns 12,000 shares of the company’s stock, valued at approximately $309,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Eric Bjerkholt purchased 2,000 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was bought at an average cost of $25.80 per share, with a total value of $51,600.00. Following the completion of the acquisition, the chief financial officer now owns 12,000 shares of the company’s stock, valued at approximately $309,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Peter Radovich sold 4,303 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $25.80, for a total value of $111,017.40. Following the completion of the transaction, the chief operating officer now directly owns 29,013 shares of the company’s stock, valued at $748,535.40. The disclosure for this sale can be found here. 24.06% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. raised its stake in shares of Mirum Pharmaceuticals by 98.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company’s stock worth $31,000 after buying an additional 488 shares during the period. Los Angeles Capital Management LLC raised its stake in shares of Mirum Pharmaceuticals by 1.2% during the 3rd quarter. Los Angeles Capital Management LLC now owns 42,444 shares of the company’s stock worth $1,341,000 after buying an additional 494 shares during the period. Royal Bank of Canada raised its stake in shares of Mirum Pharmaceuticals by 40.1% during the 2nd quarter. Royal Bank of Canada now owns 1,851 shares of the company’s stock worth $48,000 after buying an additional 530 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Mirum Pharmaceuticals by 4.9% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,037 shares of the company’s stock worth $358,000 after buying an additional 654 shares during the period. Finally, Swiss National Bank raised its stake in shares of Mirum Pharmaceuticals by 1.3% during the 3rd quarter. Swiss National Bank now owns 54,400 shares of the company’s stock worth $1,719,000 after buying an additional 700 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.